The Landmark Discovery That Paved the Way to a Mechanistic Understanding of P53 Gain of Function and Personalized Medicine.

Abstract

In 1990, Baker and colleagues reported their seminal findings in <i>Cancer Research</i> focusing on the transition from adenoma to carcinoma of the colon. By sequencing the <i>TP53</i> locus in 58 colorectal tumors (25 adenomas and 33 carcinomas) and measuring its allelic deletions, they discovered that this transition requires the loss of one <i>TP53</i> allele and the mutation of the other one. Here, we discuss how this landmark discovery shed a new light on p53 mutations, prompting the generation of novel mouse models that definitively proved the mutant p53 gain-of-function hypothesis suggested by these results. Finally, we evaluate the implications that the Vogelstein model of cancer progression had on numerous aspects of cancer biology and cancer care, including the characterization of tumor evolution and the response to therapy, and how it ultimately contributed to the wider adoption of early detection screenings and personalized medicine.<i>See related article by Baker and colleagues, Cancer Res 1990;50:7717-22</i>.